3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Skin Neoplasms
3
Carcinoma, Basal Cell
3
Dermatofibrosarcoma
2
Surgical Wound
1
Nonmelanoma Skin Cancer
1
Neoplasms, Adnexal and Skin Appendage
1
Melanoma
1
Histiocytoma, Malignant Fibrous
1
Cicatrix
1
Carcinoma, Squamous Cell
1
Interventions
Doxorubicin
13
Ifosfamide
10
Radiotherapy
6
Sunitinib
3
pegfilgrastim
2
Trabectedin
2
Radiotherapy, Conformal
2
Nivolumab
2
Methotrexate
2
Ipilimumab
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Cisplatin
2
Chemotherapy, Adjuvant
2
tremelimumab
1
temsirolimus
1
soblidotin
1
saracatinib
1
romidepsin
1
ribociclib
1
reolysin
1
perifosine
1
pembrolizumab
1
pazopanib
1
olaratumab
1
montanide ISA 51
1
liposomal doxorubicin
1
indolepropanol phosphate
1
exatecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Histiocytoma, Malignant Fibrous
×
Mohs Surgery
×
Clear all
NCT02310503
2020-05-05
REGESMOHS
Fundación Academia Española de Dermatología
Completed
6,000 enrolled